Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking clinical milestones, R&D burn, and dilution risk inside Artiva Biotherapeutics’ SEC filings can feel like piecing together a lab notebook. Pages of data on AlloNK® manufacturing, CAR-NK pre-clinical readouts, and GC Cell licensing terms stretch across 10-K sections most investors skim. Stock Titan’s AI pinpoints what matters—whether it is the exact cash runway disclosed in an 8-K, or fresh Artiva Biotherapeutics insider trading Form 4 transactions before a trial update.
Use our platform to jump straight to the numbers and narratives hidden in each document type. The annual report 10-K simplified shows year-over-year R&D trends, while every Artiva Biotherapeutics quarterly earnings report 10-Q filing is paired with plain-English summaries of pipeline spend and collaboration revenue. Need an alert when executives file? Our real-time feed captures Artiva Biotherapeutics Form 4 insider transactions real-time so you see buying or selling the moment it hits EDGAR. Proxy statement executive compensation details, 8-K material events explained, shelf registrations, and S-1 drafts are all indexed, searchable, and annotated by AI.
Whether you’re modeling future financing rounds, comparing segment spending, or simply understanding Artiva Biotherapeutics SEC documents with AI, Stock Titan delivers every filing the instant it is accepted. Investors monitor pipeline catalysts, analysts follow Artiva Biotherapeutics earnings report filing analysis, and governance specialists review the Artiva Biotherapeutics proxy statement executive compensation tables—all without wading through biotech jargon. Save hours, gain clarity, and act on insights that conventional data feeds miss.
RA Capital Management reported changes in beneficial ownership of Artiva Biotherapeutics (ARTV) through a Form 4 filing. The key transaction involves the grant of 13,750 stock options to Laura Stoppel, a Partner at RA Capital who serves on Artiva's board, on June 24, 2025.
Key details of the stock option grant:
- Exercise price: $1.61 per share
- Vesting date: Earlier of June 24, 2026, or 2026 annual stockholder meeting
- Expiration date: June 23, 2035
Notable governance structure: The options are held for the benefit of RA Capital's funds (Healthcare Fund, Nexus Fund, and Nexus Fund III) and a managed account. Dr. Stoppel must transfer any proceeds to RA Capital to offset advisory fees. The filing includes multiple reporting persons, including Peter Kolchinsky and Rajeev Shah as managing members of RA Capital Management GP, who maintain significant ownership positions as both directors and 10% owners.
Artiva Biotherapeutics, Inc. (ARTV) disclosed a routine insider transaction in a Form 4 filing. On 24 June 2025, director Alison Moore received a stock option for 13,750 common shares at an exercise price of $1.61 per share. The option vests in full on the earlier of 24 June 2026 or the company’s 2026 annual shareholder meeting and expires on 23 June 2035. Following the grant, Moore beneficially owns 13,750 derivative securities, held directly. No shares were bought or sold in the open market, and there were no accompanying cash transactions.
The filing reflects standard director compensation and does not signal changes to Artiva’s operating outlook, capital structure, or near-term liquidity.
Form 4 Filing Details: Daniel G. Baker, Director of Artiva Biotherapeutics (ARTV), received a stock option grant for 13,750 shares of common stock on June 24, 2025.
Key transaction details:
- Option exercise price set at $1.61 per share
- Full vesting occurs on the earlier of June 24, 2026, or the 2026 annual stockholder meeting
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Neha Krishnamohan as attorney-in-fact on June 26, 2025.
Elizabeth L. Hougen, Director at Artiva Biotherapeutics, reported receiving a stock option grant on June 24, 2025. The derivative securities transaction involved:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will vest fully on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
- Options expire on June 23, 2035
This Form 4 filing represents a standard director compensation equity grant. The options were granted with a 1-year cliff vesting schedule, suggesting alignment with the company's annual director service period. The transaction was executed under direct ownership, with the filing made through an attorney-in-fact on June 26, 2025.
Laura Stoppel, Director at Artiva Biotherapeutics (ARTV), received a stock option grant on June 24, 2025. The grant consists of 13,750 options to purchase common stock at an exercise price of $1.61 per share. The options will fully vest on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting.
Notable disclosure: Under an arrangement with RA Capital Management, Stoppel holds these options for the benefit of multiple funds: R.A. Capital Healthcare Fund, R.A. Capital Nexus Fund, Nexus Fund III, and a separately managed account. She must turn over any proceeds from exercise to RA Capital Management to offset advisory fees, and therefore disclaims beneficial ownership of both the options and underlying common stock.
The options have a ten-year term, expiring on June 23, 2035. This Form 4 was filed via attorney-in-fact Neha Krishnamohan on June 26, 2025.
Artiva Biotherapeutics Director Gines Diego Miralles received a stock option grant on June 24, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options expire on June 23, 2035
- Full vesting occurs on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting
The filing was executed by Neha Krishnamohan as attorney-in-fact on June 26, 2025. This transaction represents a standard director compensation equity grant, with Miralles holding direct ownership of these derivative securities.
Director Brian Daniels of Artiva Biotherapeutics was granted stock options on June 24, 2025. The key details of this insider transaction include:
- Received 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will expire on June 23, 2035
- Vesting schedule: 100% vesting on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
This grant appears to be part of the company's director compensation program. The transaction was reported via Form 4 filing and executed through an attorney-in-fact, Neha Krishnamohan. The options represent a new position for the director, as no prior holdings were reported in the filing.
FAQ
What is the current stock price of ARTIVA BIOTHERAPEUTICS (ARTV)?
What is the market cap of ARTIVA BIOTHERAPEUTICS (ARTV)?
What is the primary focus of Artiva Biotherapeutics Inc?
What makes AlloNK® different from other cell therapies?
How does Artiva generate revenue through its business model?
What are the primary therapeutic areas Artiva is addressing?
How does Artiva’s clinical research strategy differentiate it from competitors?
What role does Artiva’s partnership with GC Cell play in its operations?
In what way does Artiva enhance the effect of monoclonal antibodies?
What should investors understand about Artiva’s market position?
